António Cabral Lopes, Olga Lourenço, Sandra Morgado, Andreia Gaspar, Idalina Freire, Inês Eusébio, João Ribeiro, Mafalda Silva, Marta Mendes, Olímpia Fonseca, Rute Duarte, Manuel Morgado
Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), has shown demonstrated benefits for renal and cardiovascular outcomes in large clinical trials. However, short-term concerns regarding its impact on renal function and electrolyte balance exist. This study aimed to evaluate the short-term effects of dapagliflozin on renal function and electrolyte balance in patients newly prescribed the medication. A retrospective analysis of 246 patients who initiated dapagliflozin therapy was conducted. Serum creatinine, sodium, and potassium levels were measured at baseline (before dapagliflozin) and 5-8 days after initiation (endpoint)...
March 26, 2024: Pharmaceuticals